All posts by medical

OU College of Medicine > Academic Departments > Internal …

There are 12 clinical and research Faculty in the Rheumatology, Immunology and Allergy Section (RIA) University of Oklahoma and Oklahoma Medical Research Foundation combined research program. Please access the OMRF web sitehereto find a description of their research interests and recent publications.

The research program of the Rheumatology, Immunology and Allergy Section(RIA) of the Department of Medicine at the University of Oklahoma Health Sciences Center (OUHSC) is integrated with the Arthritis and Clinical Immunology Research Program at theOklahoma Medical Research Foundation(OMRF). Research faculty is assigned research space at both the Oklahoma Medical Research Foundation and the University of Oklahoma Health Sciences Center.

Most of the work underway is unified under autoimmunity or inflammation. Systemic lupus erythematosus is a particular focus of many of the faculty. Our investigators lead large, multi-investigator projects such as Centers of Biomedical Research Excellence in Immunology and Autoimmunity, the Oklahoma Rheumatic Disease Research Cores Center, Autoimmunity Center of Excellence and Center of Research Translation in Sjogrens syndrome. We house a number of large patient collections in diseases such as systemic lupus erythematosus, Sjgrens syndrome, rheumatoid arthritis and related disorders. In addition, the faculty has available a CLIA approved laboratory for the serologic diagnosis of lupus and other autoimmune rheumatic disease syndromes.

Excerpt from:
OU College of Medicine > Academic Departments > Internal ...

Dr. Amir Bajoghli’s Article on Shiitake Mushroom Dermatitis Featured in Premier Immunology Publication – Yahoo Finance

MCLEAN, VA / ACCESSWIRE / May 29, 2020 / The shiitake is an edible mushroom native to East Asia. The popularity of these mushrooms has increased over the years in the United States and with it has been a rise in allergic skin reactions to this relatively new ingredient on the American culinary landscape.

Shiitake flagellate dermatitis, also known as toxicoderma, is an allergic reaction related to the ingestion of raw or undercooked shiitake mushrooms. Signs of this dermatologic condition include skin eruptions resembling scratch or whiplash marks. This skin reaction occurs in approximately 2-3% of people who eat undercooked or raw shiitake mushrooms.

Various theories exist as to how and why this type reaction occurs with some people who eat the undercooked forms of the edible fungus.

When Dr. Amir Bajoghli of Skin & Laser Dermatology Center recently treated such a case in his practice, he realized it was of importance to share his medical findings regarding the patient with the scientific community. He wrote up the details of this Shiitake mushroom dermatitis. These findings were published in the Annals of Allergy, Asthma & Immunology, the premier publication for allergic and immunologic diseases.

Dr. Bajoghli is honored to publish the case with his father, Dr. Mehdi Bajoghli, a practicing allergist in Northern Virginia.

Dr. Amir Bajoghli has been active in the practice of dermatology and laser surgery since the completion of his training at the combined Tufts University and Boston University. He regularly presents lectures to other physicians regionally and internationally, and teaches medical students and dermatology residents at Georgetown University.

Dr. Amir Bajoghli can be reached at either of his Virginia offices:

McLean:1359 Beverly Rd., 2nd FloorMcLean, VA 22101(703) 893-1114

Woodbridge:2200 Opitz Blvd., Suite 100Woodbridge, VA 22191(703) 492-4140

SOURCE: Skin and Laser Dermatology Center

View source version on accesswire.com: https://www.accesswire.com/591993/Dr-Amir-Bajoghlis-Article-on-Shiitake-Mushroom-Dermatitis-Featured-in-Premier-Immunology-Publication

Excerpt from:
Dr. Amir Bajoghli's Article on Shiitake Mushroom Dermatitis Featured in Premier Immunology Publication - Yahoo Finance

Burnham recognized by national microbiology society – Washington University School of Medicine in St. Louis

Visit the News Hub

Honored for research and leadership in clinical microbiology

Burnham

Carey-Ann D. Burnham, PhD, a professor of pathology and immunology at Washington University School of Medicine in St. Louis, has received the Award for Research and Leadership in Clinical Microbiology from the American Society for Microbiology. The award recognizes an outstanding scientist and clinical microbiologist with distinguished research achievements and a record of innovation who has advanced the profession of clinical microbiology.

Also a professor of medicine, of molecular microbiology and of pediatrics, Burnhams research focuses on antimicrobial resistance. She is particularly interested in how multidrug-resistant organisms arise and spread, especially within hospitals, and in developing novel diagnostic methods for detecting drug-resistant strains of bacteria such as Staphylococcus aureus and Clostridium difficile.

Burnham is the medical director of clinical microbiology at Barnes-Jewish Hospital, as well as the program director for the universitys postdoctoral fellowship training program in medical and public health microbiology, and the vice chair of faculty mentoring and advancement in the Department of Pathology & Immunology. Currently, she is part of the leadership team developing diagnostic and antibody tests for COVID-19.

See the article here:
Burnham recognized by national microbiology society - Washington University School of Medicine in St. Louis

Researchers review all clinical and research findings related to COVID-19 – News-Medical.Net

Due to the devastating worldwide impact of COVID-19, the illness caused by the SARS-CoV-2 virus, there have been unprecedented efforts by clinicians and researchers from around the world to quickly develop safe and effective treatments and vaccines.

Given that COVID-19 is a complex new disease with no existing vaccine or specific treatment, much effort is being made to investigate the repurposing of approved and available drugs, as well as those under development.

In Frontiers in Immunology, a team of researchers from the U.S. Food and Drug Administration reviews all of the COVID-19 clinical and research findings to date.

They provide a breakdown of key immunological factors underlying the clinical stages of COVID-19 illness that could potentially be targeted by existing therapeutic drugs.

Dr. Montserrat Puig of the U.S. Food and Drug Administration, the senior author of the review, stated that "there are multiple factors involved in determining if the patient's immune response will be insufficient or successful in combating the infection."

"Our review is an overview of these factors and how they can be considered to define the context in which medications currently used for other diseases, or development of novel agents, can be utilized to prevent, ameliorate or cure COVID-19."

We know that during the early stage of COVID-19 people can show no symptoms or mild symptoms, and for many, the disease resolves.

For others, it can be catastrophic. The illness can progress to a severe stage with manifestations including Acute Respiratory Distress Syndrome, accompanied by severe lung inflammation and damage.

Patients with severe COVID-19 are often admitted to intensive care units and require life support with medical ventilation.

This review compiles and summarizes published up-to-date studies unraveling the factors leading to the cytokine storm and its consequences observed in COVID-19, including the immunological events underlying the severe manifestation of the disease.

The analysis is further supplemented with knowledge previously acquired from other coronaviruses including SARS-CoV and MERS-CoV.

The authors underscore key immunological events that might tip the balance from a protective to a hyperinflammatory response leading to life-threatening conditions.

They outline a promising list of currently available drugs that are either understudy or under consideration for use in COVID-19 based on their potential to influence these key immunological events.

These drugs include those that could inhibit SARS-CoV-2 entry into host cells, antivirals with the potential to block SARS-CoV-2 replication or factors that could boost the antiviral response, monoclonal antibodies targeting pro-inflammatory cytokines that drive the hyperinflammatory response and therapeutics that could improve the function of the lungs.

Puig states that "approaches to therapy in the early stage of the disease will differ from those in its severe late stage."

Adding that "as the results of clinical trials become available, it may become increasingly clear that there is likely no single magic bullet to resolve the disease but a combination of several interventions that target different key factors of COVID-19 may well be required."

Puig cautions that "the research and data obtained from COVID-19 studies are rapidly evolving and continuously updated. Thus, as clearly stated in our review, the information provided is a 'lessons learned' to date and describes the knowledge available at the time of the publication of the review."

The description of the immunological profile of the clinical stages of COVID-19 provided in this review will enable more informed decisions about the type and timing of treatments to be evaluated in clinical trials.

Our hope is that the information contained in our review will help professionals in COVID-19 research develop new tools and agents to better treat those at high risk of severe COVID-19."

Dr. Montserrat Puig, Study Senior Author, U.S. Food and Drug Administration

Source:

Journal reference:

Cardone, M., et al. (2020) Lessons Learned to Date on COVID-19 Hyperinflammatory Syndrome: Considerations for Interventions to Mitigate SARS-CoV-2 Viral Infection and Detrimental Hyperinflammation. Frontiers in Immunology. doi.org/10.3389/fimmu.2020.01131.

Read more from the original source:
Researchers review all clinical and research findings related to COVID-19 - News-Medical.Net

CSU cancer researcher named 2020 Boettcher Investigator – Source

Dan Regan, an assistant professor in Microbiology, Immunology, and Pathology, was recently selected to receive the Boettcher Foundations 2020 Webb-Waring Biomedical Research Award.

The award supports promising early-career scientific investigators, allowing them to establish their independent research and make it competitive for major federal and private grants.Recipients, known as Boettcher Investigators, are awarded $235,000 to sustain up to three years of biomedical research. Regan joins seven other recipients from five of Colorados top research institutions and is the 12th scientist at Colorado State University to receive the award.

I am grateful to the Boettcher Foundation for their commitment to biomedical research, said Regan. This award provides a fantastic opportunity to gain momentum and make an impact in my field.

This class of Boettcher Investigators are the example of Colorados innovation in bioscience research that aims to improve our preparation, response, and deepen our knowledge of human health issues, said Katie Kramer, president, and CEO of the Boettcher Foundation. We are proud to support their expert work at this significant juncture in their research careers.

Regans work in metastatic cancer research at his Investigational Pathology Lab at the Flint Animal Cancer Center caught the attention of the Boettcher Foundation.

Many types of cancer, in both pets and people, spread to the lungs, Regan said. Once cancer progresses, we have few treatment options. My work focuses on looking at tumor metastasis through the lens of the tumor microenvironment.

Regan has spent the last decade examining the tumor microenvironment and why some sites in the body promote tumor growth. He explains his work with a simple analogy known as the seed and soil theory. He wants to understand how cancer cells (seeds) know where to find welcoming locations to take root (soil).

With the Boettcher Investigator award, Regan is taking a new approach to his study of metastatic disease. In a unique application, Regan is looking at cells retrieved from the lungs using a diagnostic procedure called bronchoalveolar lavage. The technique uses fluid to wash the lungs and extracts the fluid for examination. Regan has reason to believe certain types of recovered cells have the potential to signal an early warning of tumor metastasis.

Todays imaging technology, such as CT scans, detects tumors, but it can be too late, he said. Biopsies are very invasive. Using this procedure, if we can find earlier clues, we can better guide treatment and hopefully improve patient outcomes.

Building on his preliminary work, Regan plans to spend the next several months gathering additional data from donated human cells and mouse models. The goal is to identify which cell type offers the best signature for early detection.

In addition to laboratory study, the award supports a small clinical trial in dogs with Osteosarcoma, a disease in which 80% of patients experience lung metastasis. Regan will focus on patients who do not appear to have pulmonary tumors based on imaging. Using bronchoalveolar lavage, he will collect patient samples to look for red flags in the retrieved cells. He expects the trial to start sometime next year.

I am grateful to the Boettcher Foundation for their support and taking a chance on a higher risk concept that I believe has the power to pay real dividends for pet and human health, Regan said.

Continue reading here:
CSU cancer researcher named 2020 Boettcher Investigator - Source

Dispersed across globe, Brown community finds connection through ‘Dank Stash of Memes’ – The Brown Daily Herald

Richard Bungiro PhD99, senior lecturer in molecular microbiology and immunology, structures his course BIOL 0530: Principles of Immunology around pop culture themes. He challenges students to untangle the hypothetical immunological functions of a Terminator or a dragon. He has an antibody tattooed on his wrist. And he makes memes, which he posts on a Facebook page frequented by hundreds of his current and former students.

Whats your favorite administrative euphemism for global pandemic? Bungiro asked in one of his recent posts. These trying times. These difficult times. These uncertain times. These challenging times. Protect the endowment at all times.

He posted the meme to Brown Dank Stash of Memes for S/NC Teens, a Facebook page where over 20,000 members upload and interact with Brown-related meme content. Over the past four years, the page has become a cultural touchstone for students at Brown. Now, with campus closed as a result of the COVID-19 pandemic, the meme page has helped recreate community for students isolated in their homes. The memes themselves have become a form of communication, of transmitting meaning, that is uniquely suited to the digital existence the Brown community has adopted.

I think people really want to feel like theyre part of a community, Bungiro said. Being on that page and some of the other ones, I think its a way for people to retain a little piece of what were all missing so much right now.

Memes emerged as a cultural phenomenon in the early 2000s, taking the internet and college campuses alike by storm. The word meme was coined to describe elements of culture that propagate through society, particularly through imitation, and are stuck easily to humorous images created and shared through the internet.

Right now this is one of the only public forums that Brown students have as a community, said Lucy Duda 20, a senior administrator of the page as well as a moderator of The Ivy League Meme Consortium, a similar Facebook page with over 100,000 members focused on Ivy League content. Weve really tried to make the meme page a space for public discourse in the community and a way for people to find common ground and bond over how terrible a lot of things have been.

Duda became a moderator of Browns meme page in the fall of 2016, when the page only had a few hundred members. She has seen it grow ever since. In honor of the page hitting 20,000 members, Duda recently made a new cover photo reading Brown Digital Space Main Green.

Throughout the quarantine, memes have poked fun at decisions from the University administration and questioned, often sarcastically, whether students will return to campus this fall. There has also been an influx of more comical content, such as a group of cel-shaded bears dancing to Smash Mouth. Beneath those boogying bears and agitated students lie hundreds of comments of friends tagging each other and reaching out, despite distance and uncertainty, hoping to make each other laugh.

The undertone is very much that things suck, but we can do this, said Elliott Lehrer 21, who has posted memes since he was accepted to Brown three years ago.

Hannah Kierszenbaum 20, who spent her senior spring on College Hill with a few friends, said the meme page has helped keep her connected to the greater Brown community. I relate to it and look at it more now that were in quarantine, she said. It is a subpar situation for everybody so its cathartic to know that other people are also struggling.

These memes will endure beyond the pandemic. Researchers at the University are archiving them at the request of the administrative team behind Brown Dank Stash of Memes for S/NC Teens. Nationally, the Library of Congress is doing the same for other meme content.

John Fenn, contributor to the Library of Congress web archive and head of research and programs at the American Folklife Center, emphasized the communal power of this form of communication, which he defines as narrative, visual communication, contemporary humor that arises out of a collective sense of something, even if its not a collective experience.

Its a fascinating kind of archaeology, Fenn said. Its the archeology of right now.

Andrew Majcher, head of digital services and records management in the John Hay Library, agreed with Fenn.

Especially with the way the COVID crisis has been going, its one of the more poignant ways we can gauge how the student body is feeling about whats going on, Majcher said.

Majcher added that the meme page, along with other pages like Poems from a University Quarantine, might be included in a future University library project on digital documentation of the pandemic.

The lasting impact of the meme page has come as a surprise for Dylan Garcia 20, who co-founded the meme group four years ago.

At the beginning, I thought it was just going to be general memes, Garcia said, who thought that around 2,000 members would join, one-tenth of its current following. He didnt know that the page would end up putting a voice on some issues.

The typical end of the year atop College Hill is Spring Weekend, packed libraries, finals and a stately procession through the Van Wickle Gates. Not this year; no crowded moshes, no late nights in the Rock and Commencement was a half-hour online. Bungiro captured that transition and his feelings toward the community in a meme, composed of a photo of the gates above a photo of his orange couch at home.

Not much snark or spicy in this meme, my friends just sincere gratitude for the students of Brown, the caption reads. You matter, and you constantly remind me why it matters.

Go here to see the original:
Dispersed across globe, Brown community finds connection through 'Dank Stash of Memes' - The Brown Daily Herald

Kiniksa Announces Upcoming Presentation on Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation at the European E-Congress of Rheumatology 2020 -…

HAMILTON, Bermuda, May 29, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (KNSA) (Kiniksa), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced an upcoming presentation, entitled Mavrilimumab Improves Outcomes in Severe COVID-19 Pneumonia and Systemic Hyper-Inflammation, showing data from the open-label treatment protocol with mavrilimumab, an investigational fully-human monoclonal antibody that targets granulocyte macrophage colony stimulating factor receptor alpha (GM-CSFR), in patients with severe coronavirus 2019 (COVID-19) pneumonia and hyperinflammation will be delivered at the European E-Congress of Rheumatology (EULAR) 2020. Additionally, preclinical data analyzing the role of the granulocyte macrophage colony stimulating factor (GM-CSF) pathway in giant cell arteritis (GCA) pathophysiology will be included in a poster presentation.

ProfessorLorenzo Dagna, MD, FACP, Head, Unit of Immunology, Rheumatology,Allergy and Rare Diseases IRCCS San Raffaele Scientific Institute andVita-Salute San Raffaele UniversityinMilan, Italywill deliver an oral presentation of outcomes data from the mavrilimumab treatment protocol in COVID-19 pneumonia and hyperinflammation in Italy.

Oral Presentation Details:

There will also be a presentation of preclinical data analyzing the role of the GM-CSF pathway in GCA pathophysiology delivered by Dr.Maria C. Cid, MD, Hospital Clnic,University ofBarcelona, Institut dInvestigacions BiomdiquesAugust Pii Sunyer (IDIBAPS), Vasculitis Research Unit,Department of Autoimmune Diseases,Barcelona,Spain.

Poster Presentation Details:

Kiniksa intends to make the presentations available through the Science section of Kiniksas website (www.kiniksa.com) after the EULAR embargo lifts, which is expected to be at the time of each presentation.

1IRCCS San Raffaele Scientific Institute, Milan, Italy; 2Vita-Salute San Raffaele University, Milano, Italy; 3Kiniksa Pharmaceuticals, Lexington, United States of America; 4Vasculitis Research Unit, Hospital Clinic, University of Barcelona, IDIBAPS.

About MavrilimumabMavrilimumab is an investigational fully-human monoclonal antibody that is designed to antagonize granulocyte macrophage colony stimulating factor (GM-CSF) signaling by binding to the alpha subunit of the GM-CSF receptor. Kiniksas lead indication for mavrilimumab is giant cell arteritis (GCA), an inflammatory disease of medium-to-large arteries. Mavrilimumab was dosed in over 550 patients with rheumatoid arthritis through Phase 2b clinical studies in Europe and achieved prospectively-defined primary endpoints of efficacy and safety. Additionally, Kiniksa and Kite have a clinical collaboration to evaluate mavrilimumab in combination with Yescarta (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma.

About the Mavrilimumab Treatment Protocol in COVID-19 Pneumonia & Hyperinflammation in ItalyThe mavrilimumab open-label treatment protocol was a prospective, interventional, single-active-arm, single-center pilot experience inItaly conducted by Professor Lorenzo Dagna, MD, FACP, Head, Unit of Immunology, Rheumatology, Allergy and Rare Diseases IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University in Milan, Italy within a COVID-19 Program directed by Professor Alberto Zangrillo, Head of Department of Anesthesia and Intensive Care of the Scientific Institute San Raffaele Hospital and Universit Vita-Salute San Raffaele in Milan, Italy. Patients suffering from severe pulmonary involvement of COVID-19, acute respiratory distress, fever, and clinical and biological markers ofsystemic hyperinflammation status were treated with a single intravenous dose of mavrilimumab. The objective of the treatment protocol was to determine whether mavrilimumab in addition to standard management could improve clinical outcomes in patients with COVID-19 pneumonia and hyperinflammation. A control-group was assembled consisting of contemporaneous patients receiving local standard of care and matched for age, sex, comorbidities, baseline inflammatory markers and respiratory dysfunction. Per standard of care of the hospital, all patients received on admission medical treatment with hydroxychloroquine, azithromycin, and lopinavir/ritonavir as well as respiratory support with supplemental oxygen and/or non-invasive ventilation with continuous positive airway pressure.

Story continues

About KiniksaKiniksa is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksas clinical-stage product candidates, rilonacept, mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions, and offer the potential for differentiation. These pipeline assets are designed to modulate immunological signaling pathways that are implicated across a spectrum of diseases. For more information, please visit http://www.kiniksa.com.

Every Second Counts!

Kiniksa Investor and Media ContactMark Ragosa(781) 430-8289mragosa@kiniksa.com

Read the original:
Kiniksa Announces Upcoming Presentation on Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation at the European E-Congress of Rheumatology 2020 -...

RAPT Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Virtual Scientific Program – GlobeNewswire

SOUTH SAN FRANCISCO, Calif., May 29, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical companyfocused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the presentation of a Trials in Progress poster for the ongoing seamless Phase 1/2 clinical trial of FLX475, a small molecule CCR4 antagonist in development for multiple tumor types. The poster was presented at the American Society of Clinical Oncology (ASCO) 2020.

The poster presentation detailed previously reported initial Phase 1 healthy volunteer data for FLX475 that demonstrated excellent safety, pharmacokinetics (PK) and target engagement. FLX475 is designed to block regulatory T cells from migrating to tumor sites, where they suppress immune system responses to cancer cells, without depleting regulatory T cells in the rest of the body nor immune cells required for an anti-tumor response. A robust pharmacodynamic (PD) assay measuring receptor occupancy on circulating regulatory T cells demonstrated that FLX475 achieved exposure levels over the targeted 75%, predicting maximal inhibition of regulatory T cell recruitment into tumors via CCR4 signaling. In addition, levels of FLX475 increased in a dose-proportional manner, with a strong PK/PD correlation observed between drug levels and receptor occupancy.

Building on these data, RAPT initiated a seamless Phase 1/2 study of FLX475. The Phase 1 portion of the trial was a standard dose escalation study in patients with many types of cancer, and the Phase 2 portion is evaluating FLX475 both as monotherapy and in combination with a checkpoint inhibitor in patients with charged tumors, which are tumors that express high levels of CCR4 ligands (CCL17 and CCL22), and have a high presence of regulatory T cells and CD8+ effector T cells. RAPT is currently enrolling the Phase 2 portion of the trial in patients with charged tumors, including non-small cell lung cancer, triple negative breast cancer, head and neck squamous cell carcinoma, cervical cancer as well as EBV-positive nasopharyngeal cancer and lymphomas.

We are pleased with our continued progress in clinical evaluation of FLX475 and remain encouraged by our early observations, said Brian Wong, M.D., Ph.D., President and CEO of RAPT Therapeutics. The previously reported checkpoint inhibitor-refractory patient with non-small cell lung cancer with a confirmed partial response in the Phase 1 part of this study continues to respond to FLX475 plus Keytruda, and is approaching the 1-year mark of study treatment. Our sites in the U.S., Australia and Asia continue to enroll patients and we remain on track to report results for both the Phase 1 and initial Phase 2 expansion cohorts in the second half of 2020.

The poster presented at ASCO can be viewed on the RAPT website under the Events and Presentation tab of the Investor Relations section here.

About FLX475FLX475 is a small molecule CCR4 antagonist designed to block the migration of regulatory T cells (Treg) specifically into tumors, but not healthy tissues. Tregrepresent a dominant pathway for downregulating the immune response, and may limit the effectiveness of currently available therapies such as checkpoint inhibitors. RAPT is developing FLX475 for the treatment of a broad range of charged tumors, which represent cancer types the company believes are most likely to respond to FLX475, where a large quantity of Tregcells are likely to be the cause of immune suppression within the tumor. FLX475 blocks the migration of Tregto the tumor, which may restore naturally occurring antitumor immunity and synergizing with a variety of both conventional and immune-based therapies, such as radiation, chemotherapy, checkpoint inhibitors, immune stimulators and adoptive T cell therapy.

AboutRAPT Therapeutics, Inc.RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets, including hematopoietic progenitor kinase 1 (HPK1) and general control nonderepressible 2 (GCN2), that are in the discovery stage of development.

Forward-Looking StatementsThis press release contains forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future performances or achievements expressed or implied by the forward-looking statements. Each of these statements is based only on current information, assumptions and expectations that are inherently subject to change and involve a number of risks and uncertainties. Forward-looking statements include, but are not limited to, statements about the clinical development of FLX475, the interpretation of preliminary observations from the Phase 1 cohort in FLX475 and the continued progress and timing of results from clinical trials of FLX475. Detailed information regarding risk factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in RAPTs Form 10-Q filed with the Securities and Exchange Commission on May 14, 2020 and subsequent filings made by RAPT with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. RAPT disclaims any obligation to update these forward-looking statements.

RAPT Media Contact:Angela Bittingmedia@rapt.com(925) 202-6211

RAPT Investor Contact:Sylvia Wheelerswheeler@wheelhouselsa.com

Read the original here:
RAPT Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Virtual Scientific Program - GlobeNewswire

To vax or not to vax: Pitt scientist discusses importance of vaccines – The Times

A recent poll shows that half of Americans say theyll get a COVID-19 vaccination when it becomes available.

Only about half of Americans in a recent poll say theyll get a COVID-19 vaccination when it becomes available, according to a recent study. A Pittsburgh-based immunology expert said he hopes they change their minds.

The Associated Press-NORC Center for Public Affairs Research found that if a vaccine against coronavirus becomes available to the public, only about half of those polled said they plan to get vaccinated; 20 percent said they will not; and about a third of those polled are not sure.

I advocate vaccines. They clearly have been shown to be safe in multiple studies, said Dr. William Klimstra, a professor of immunology at the University of Pittsburgh, during a Facebook Live discussion with Auditor General Eugene DePasquale. You just have to basically accept when you have essentially universal consensus among people who should know about something, in this case that vaccines are safe.

The top reason folks said they would be less inclined to get the vaccine is because of safety, particularly fear of potential side effects of the vaccine.

Seven out of 10 people polled who do not plan to get the vaccine said they are concerned about the side effects with nearly half being concerned with contracting the coronavirus. About one in three said they are not concerned about getting seriously ill from the virus.

Dr. William Klimstra, who works in the Department of Immunology and the Microbiology and Molecular Genetics Department at the University of Pittsburgh, is a member of the Center for Virus Research. An advocate of vaccines, he has been involved in several previous vaccine designs.

Klimstra spoke with Pennsylvania Auditor General Eugene DePasquale during a Facebook Live session on Wednesday and said the anti-vaccine rhetoric on social media and parts of the internet should not be accepted by anybody who thinks about this critically.

Were in an environment right now where long-standing excepted truths are being challenged through social media and other things, he said. Ive read a lot of the anti-vaccine literature and things that are on the internet, and people seem to feel Big Pharma is promoting these things and then scientists because they get grants. They have been compromised because of Big Pharma.

Klimstra said that vaccines are advocated by doctors, because theyre proven to be safe and effective.

I advocate vaccines. They clearly have been shown to be safe in multiple studies, he said. You just have to basically accept when you have essentially universal consensus among people who should know about something, in this case that vaccines are safe.

One argument against vaccines is that it causes autism, which Klimstra says, has been debunked completely.

Safety is scientists foremost priority when it comes to vaccine creation, Klimstra said. This is why its taking months to create a COVID-19 vaccine, he said.

The reason that its taking longer a frustratingly long time to get a coronavirus vaccine in the marketplace is because of the safety testing, he said.

Klimstra said people can have adverse reactions to vaccines. But its just vanishingly small with vaccines. And the links to autism are just not held up by science, he said.

Hundreds of millions of lives have been saved because of vaccines, Klimstra stressed.

Looking back, historically vaccines are one of the most productive and important medical technologies that have ever been used, he said.

Similarly to using masks, Klimstra said its not just about keeping yourself safe vaccines help prevent transmission of the virus.

The Associated Press-NORC Center for Public Affairs Research poll showed the top reasons for the nearly half of folks who said they would get a coronavirus vaccine are about protecting them, their family and their communities from the virus.

Among those polled, four out of five said they believe a vaccine is "an important criteria" for reopening, while nearly half say it's essential. About one-third say a vaccine is not essential for reopening.

Klimstra said vaccines are proven to be effective, calling them standard medical treatments.

Weve eliminated smallpox. Polio is almost eliminated, measles was nearly eliminated until people stopped taking the vaccine, he said. You wouldnt go to the doctor and not have a treatment for a medical condition where the treatment was nearly completely safe and worked a high percentage of the time. You wouldnt do that.

And thats what a vaccine is a standard medical treatment that saves lives. You just have to listen to people who should know about the issue.

For anti-vaxxers and those who arent convinced to get the coronavirus vaccine when it eventually becomes available, Klimstra said he hopes they will change their minds.

Its a critical issue both for themselves and for other people, he said.

Klimstra called it having a protective attitude and a positive community attitude.

These vaccines will be safe. I can guarantee that, he said. Given the technologies that will be utilized, they will be safe.

See the original post here:
To vax or not to vax: Pitt scientist discusses importance of vaccines - The Times

CBD treatment improves arthritis symptoms in dogs, study finds – News-Medical.Net

Reviewed by Emily Henderson, B.Sc.May 28 2020

A team led by researchers at Baylor College of Medicine in collaboration with Medterra CBD conducted the first scientific studies to assess the potential therapeutic effects of cannabidiol (CBD) for arthritic pain in dogs, and the results could lead the way to studying its effect in humans. Researchers focused first on these animals because their condition closely mimics the characteristics of human arthritis, the leading cause of pain and disability in the U.S. for which there is no effective treatment.

Published in the journal PAIN, the study first showed both in laboratory tests and mouse models that CBD, a non-addictive product derived from hemp (cannabis), can significantly reduce the production of inflammatory molecules and immune cells associated with arthritis. Subsequently, the study showed that in dogs diagnosed with the condition, CBD treatment significantly improved quality of life as documented by both owner and veterinarian assessments. This work supports future scientific evaluation of CBD for human arthritis.

CBD is rapidly increasing in popularity due to its anecdotal health benefits for a variety of conditions, from reducing anxiety to helping with movement disorders. In 2019, Medterra CBD approached Baylor to conduct independent scientific studies to determine the biological capabilities of several of its products."

Dr. Matthew Halpert, corresponding author, research faculty in the Department of Pathology and Immunology at Baylor

In the current study, Halpert and his colleagues first measured the effect of CBD on immune responses associated with arthritis, both in human and murine cells grown in the lab and in mouse models. Using Medterra tinctures, they found that CBD treatment resulted in reduced production of both inflammatory molecules and immune cells linked to arthritis.

The researchers also determined that the effect was quicker and more effective when CBD was delivered encapsulated in liposomes than when it was administered 'naked.' Liposomes are artificially formed tiny spherical sacs that are used to deliver drugs and other substances into tissues at higher rates of absorption.

Halpert and colleagues next assessed the effect of naked and liposome-encapsulated CBD on the quality of life of dogs diagnosed with arthritis.

"We studied dogs because experimental evidence shows that spontaneous models of arthritis, particularly in domesticated canine models, are more appropriate for assessing human arthritis pain treatments than other animal models. The biological characteristics of arthritis in dogs closely resemble those of the human condition," Halpert said.

Arthritis is a common condition in dogs. According to the American Kennel Club, it affects one out of five dogs in the United States.

The 20 client-owned dogs enrolled in the study were seen at Sunset Animal Hospital in Houston. The dog owners were randomly provided with identical unidentified medication bottles that contained CBD, liposomal CBD, or a placebo. Neither the owners nor the veterinarian knew which treatment each dog received.

After four weeks of daily treatment, owners and veterinarians reported on the condition of the dogs, whether they observed changes in the animals' level of pain, such as changes related to running or gait. The dogs' cell blood count and blood indicators of liver and kidney function also were evaluated before and after the four weeks of treatment.

"We found encouraging results," Halpert said. "Nine of the 10 dogs on CBD showed benefits, which remained for two weeks after the treatment stopped. We did not detect alterations in the blood markers we measured, suggesting that, under the conditions of our study, the treatment seems to be safe."

The findings support conducting studies to evaluate CBD for the treatment of human arthritis.

Source:

Journal reference:

Verrico, C., et al. (2020) A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain. Pain. doi.org/10.1097/j.pain.0000000000001896.

See the original post:
CBD treatment improves arthritis symptoms in dogs, study finds - News-Medical.Net